According to a US commission's study, the government should invest $15 billion to strengthen the nation's position as a leader in the biotechnology industry and keep China from overtaking it.

The study, which was made public and sent to Congress on Tuesday, outlined a number of recommendations to help America develop more quickly while slowing down China. The federal government may open up private sector capital to propel a top-tier biotechnology industry by combining supply-side incentives to promote R&D and early growth with focused demand-side signals to lower investment risks.

The group also urged Congress to establish straightforward marketing channels and free well-known items from needless regulation in order to turn biotech advances into medications.

The commission noted a growing number of IP licensing agreements from Chinese biotechs, which is very concerning. About 15 of these agreements were made in 2019, compared to 33 in 2023. This year, the number is probably going to be greater because Chinese licensing agreements and their danger to US biotech were a major topic of discussion at the JP Morgan Healthcare Conference.

Congress established the National Security Commission on Emerging Biotechnology in 2021 to examine how biotechnology affects national security and offer suggestions for maintaining American leadership in the sector. Two senators, two members of the House of Representatives, seven academic specialists, and business executives make up the 11-member nonpartisan committee.